Studies Seek to Find Female Biologic Factors That Affect HIV

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 10
Volume 10
Issue 10

BETHESDA, Maryland-A 5-year, $17.5-million program will investigate how HIV infection affects adolescent and adult women. Three research centers will house the Women’s HIV Pathogenesis Program, funded by the National Institute of Child Health and Human Development (NICHD). Researchers at the centers will collaborate with others in an effort to identify biologic factors unique to women that affect HIV.

BETHESDA, Maryland—A 5-year, $17.5-million program will investigate how HIV infection affects adolescent and adult women. Three research centers will house the Women’s HIV Pathogenesis Program, funded by the National Institute of Child Health and Human Development (NICHD). Researchers at the centers will collaborate with others in an effort to identify biologic factors unique to women that affect HIV.

The centers will be located at the University of Washington in Seattle, the Gladstone Institute of Virology in San Francisco, and Rush-Presbyterian-St. Luke’s Medical Center in Chicago.

Researchers will focus on various subpopulations, including minority women, lesbians, female substance abusers, and women approaching or experiencing menopause. Understanding biologic factors unique to women could provide insights into how they become infected with the virus and transmit it to others, how the disease progresses in women after infection takes place, and how the disease affects women differently from men, NICHD said.

Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content